EYE.AX - Nova Eye Medical Limited
ASX - ASX Delayed price. Currency in AUD
At close: 04:10PM AEST
Stock chart is not supported by your current browser
| Previous close | 0.2750 |
| Open | 0.2800 |
| Bid | 0.2750 x 3603200 |
| Ask | 0.2800 x 12700 |
| Day's range | 0.2800 - 0.2900 |
| 52-week range | 0.1800 - 0.3550 |
| Volume | |
| Avg. volume | 460,557 |
| Market cap | 53.292M |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0800 |
| Earnings date | 24 Aug 2023 - 28 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 21 July 2020 |
| 1y target est | 1.00 |
Business WireNova Eye Medical Announces U.S. Market Clearance of the iTrack™ Advance Canaloplasty Device
FREMONT, Calif., April 12, 2023--Nova Eye Medical Limited (ASX: EYE) (Nova Eye Medical or the Company), a medical technology company committed to advanced ophthalmic treatment technologies and devices, today announces that it has been granted U.S. Food and Drug Administration (FDA) 510(k) clearance for its new canaloplasty device, iTrack™ Advance.